Association between mutation and expression of TP53 as a potential prognostic marker of triple-negative breast cancer

Cancer Research and Treatment

Volumn 48, Issue 4, 2016, Pages 1338-1350

  Kim, Ji Yeon ^a   Park, Kyunghee ^a   Jung, Hae Hyun ^a   Lee, Eunjin ^a   Cho, Eun Yoon ^a   Lee, Kwang Hee ^b   Bae, Soo Youn ^a   Lee, Se Kyung ^a   Kim, Seok Won ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a   Park, Yeon Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Thermo Fisher Scientific   (United States)

Author keywords

AmpliSeq; NCounter mRNA expression assay, Immunohistochemistry; Prognosis; Triple negative breast neoplasms; Tumor suppressor protein p53

Indexed keywords

MESSENGER RNA; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL OUTCOME; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; MRNA EXPRESSION ASSAY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; WILD TYPE; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SEQUENCE DELETION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84997047829     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2015.430     Document Type: Article

References (28)

1. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31.
3. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788-93.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-10.
5. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22:37-43.
6. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29:418-25.
7. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250:1233-8.
8. Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell LJ, McCowan C, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer. 2010;102: 719-26.
9. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28:622-9.
10. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by highresolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100:8424-9.
11. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861-72.
12. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525:206-11.
13. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
14. Eikesdal HP, Knappskog S, Aas T, Lonning PE. TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncol. 2014;53:1347-55.
15. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102:13550-5.
16. Vegran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One. 2013;8:e55103.
17. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26:317-25.
18. Hong D, Lee J, Bleazard T, Jung H, Ju YS, Yu SB, et al. TIARA genome database: update 2013. Database (Oxford). 2013;2013: bat003.
19. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52:2984-6.
20. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. Cancer Res. 1992;52:5291-8.
21. Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992;52:3918-23.
22. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400-4.
23. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature. 2012;486:395-9.
24. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer. 1992;50:528-32.
25. Soto-Reyes E, Recillas-Targa F. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene. 2010;29:2217-27.
26. Saldana-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics. 2011;6:1068-77.
27. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-67.
28. Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, et al. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. Int J Cancer. 2015;136: 1976-84.